Mir103 inhibitor

BPI-9016M, which is a selective small-molecular c-Met inhibitor, was kindly provided by Better Pharmaceuticals (Zhejiang, China). BPI-9016M was dissolved in 0.5% carboxymethylcellulose sodium (CMC) for PDX treatment. For other experiments, the drug was dissolved in dimethyl sulfoxide at a stock concentration of 50 mM and stored at -80 °C. The DKK1 siRNA, miR103 mimic, miR203 mimic, miR103 inhibitor and miR203 inhibitor were constructed by RiboBio (Guangzhou, China) and the pENTER-DKK1 plasmid was purchased from Vigenebio (Maryland, USA). The transfections were performed according to the protocol provided by the manufacturer (Lipo3000, Thermo Fisher, MA, USA).

The miR-103 inhibitor was designed and synthesized by RiboBio Corporation. The sequence of miR-103 inhibitor is 3'-UCA UAG CCC UGU ACA AUG CUG CU-5'. Five nucleotides or deoxynucleotides at both ends of the antisense molecules were locked.
Osteoblasts were transfected with inhibitor or negative control using Lipofectamine 2000. The medium was replaced at 6 h after transfection. The cells were collected for protein assay or patch clamp at 48 h after transfection35 (link).